191 related articles for article (PubMed ID: 32033834)
1. Whole and hemi-gland cryoablation for primary localized prostate cancer: Short and medium-term oncological and functional outcomes.
Bossier R; Sanguedolce F; Territo A; Vanacore D; MartÃnez C; Regis F; Gallioli A; Mercade A; Mosquera L; Aumatell J; Balana J; Carlderon J; Huguet J; Gaya JM; Palou J; Breda A
Actas Urol Esp (Engl Ed); 2020 Apr; 44(3):172-178. PubMed ID: 32033834
[TBL] [Abstract][Full Text] [Related]
2. Oncological and functional outcomes of men undergoing primary whole gland cryoablation of the prostate: A 20-year experience.
Tan WP; Kotamarti S; Chen E; Mahle R; Arcot R; Chang A; Ayala A; Michael Z; Seguier D; Polascik TJ
Cancer; 2022 Nov; 128(21):3824-3830. PubMed ID: 36107496
[TBL] [Abstract][Full Text] [Related]
3. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
Hubosky SG; Fabrizio MD; Schellhammer PF; Barone BB; Tepera CM; Given RW
J Endourol; 2007 Dec; 21(12):1521-31. PubMed ID: 18186694
[TBL] [Abstract][Full Text] [Related]
4. Salvage Prostate Cryoablation for the Management of Local Recurrence After Primary Cryotherapy: A Retrospective Analysis of Functional and Intermediate-Term Oncological Outcomes Associated With a Second Therapeutic Freeze.
Aminsharifi A; Jibara G; Tsivian E; Tsivian M; Elshafei A; Polascik TJ
Clin Genitourin Cancer; 2019 Aug; 17(4):e831-e836. PubMed ID: 31213413
[TBL] [Abstract][Full Text] [Related]
5. Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up.
Oishi M; Gill IS; Ashrafi AN; Lin-Brande M; Nassiri N; Shin T; Bove A; Cacciamani GE; Ukimura O; Bahn DK; Abreu ALC
Eur Urol; 2019 Feb; 75(2):208-214. PubMed ID: 30274702
[TBL] [Abstract][Full Text] [Related]
6. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years.
Bahn D; de Castro Abreu AL; Gill IS; Hung AJ; Silverman P; Gross ME; Lieskovsky G; Ukimura O
Eur Urol; 2012 Jul; 62(1):55-63. PubMed ID: 22445223
[TBL] [Abstract][Full Text] [Related]
7. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer.
Durand M; Barret E; Galiano M; Rozet F; Sanchez-Salas R; Ahallal Y; Macek P; Gaya JM; Cerruti J; Devilliers H; Loeffler J; Amiel J; Vallancien G; Cathelineau X
BJU Int; 2014 Jan; 113(1):56-64. PubMed ID: 24053685
[TBL] [Abstract][Full Text] [Related]
8. Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation.
Liu YY; Chiang PH; Chuang YC; Lee WC; Cheng YT; Wang HJ
Ann Surg Oncol; 2015 May; 22(5):1612-7. PubMed ID: 25287436
[TBL] [Abstract][Full Text] [Related]
9. Focal cryosurgical ablation of the prostate: a single institute's perspective.
Hale Z; Miyake M; Palacios DA; Rosser CJ
BMC Urol; 2013 Jan; 13():2. PubMed ID: 23311921
[TBL] [Abstract][Full Text] [Related]
10. Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry.
Dhar N; Ward JF; Cher ML; Jones JS
BJU Int; 2011 Aug; 108(4):508-12. PubMed ID: 21722288
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Outcomes Between Preoperatively Potent Men Treated with Focal Versus Whole Gland Cryotherapy in a Matched Population.
Mendez MH; Passoni NM; Pow-Sang J; Jones JS; Polascik TJ
J Endourol; 2015 Oct; 29(10):1193-8. PubMed ID: 26058496
[TBL] [Abstract][Full Text] [Related]
12. Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years.
Oishi M; Gill IS; Tafuri A; Shakir A; Cacciamani GE; Iwata T; Iwata A; Ashrafi A; Park D; Cai J; Desai M; Ukimura O; Bahn DK; Abreu AL
J Urol; 2019 Dec; 202(6):1188-1198. PubMed ID: 31347953
[TBL] [Abstract][Full Text] [Related]
13. Focal Therapy for Localized Prostate Cancer with Either High Intensity Focused Ultrasound or Cryoablation: A Single Institution Experience.
Tourinho-Barbosa RR; Sanchez-Salas R; Claros OR; Collura-Merlier S; Bakavicius A; Carneiro A; Stabile A; Moschini M; Cathala N; Tobias-Machado M; Cathelineau X
J Urol; 2020 Feb; 203(2):320-330. PubMed ID: 31437121
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of Oncological and Functional Outcomes Between Primary Whole-Gland Cryoablation and High-Intensity Focused Ultrasound for Localized Prostate Cancer.
Liu YY; Chiang PH
Ann Surg Oncol; 2016 Jan; 23(1):328-34. PubMed ID: 26088651
[TBL] [Abstract][Full Text] [Related]
15. Oncological and Functional Outcomes of Patients Undergoing Individualized Partial Gland Cryoablation of the Prostate: A Single-Institution Experience.
Tan WP; Chang A; Sze C; Polascik TJ
J Endourol; 2021 Sep; 35(9):1290-1299. PubMed ID: 33559527
[No Abstract] [Full Text] [Related]
16. Initial brazilian experience in the treatment of localized prostate cancer using a new generation cryotechnology: feasibility study.
Kim FJ; Cerqueira MA; Almeida JC; Pompeo A; Sehrt D; Calheiros JM; Martins FA; Molina WR
Int Braz J Urol; 2012; 38(5):620-6. PubMed ID: 23131504
[TBL] [Abstract][Full Text] [Related]
17. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry.
Jones JS; Rewcastle JC; Donnelly BJ; Lugnani FM; Pisters LL; Katz AE
J Urol; 2008 Aug; 180(2):554-8. PubMed ID: 18550117
[TBL] [Abstract][Full Text] [Related]
18. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement.
Deivasigamani S; Kotamarti S; Rastinehad AR; Salas RS; de la Rosette JJMCH; Lepor H; Pinto P; Ahmed HU; Gill I; Klotz L; Taneja SS; Emberton M; Lawrentschuk N; Wysock J; Feller JF; Crouzet S; Kumar M P; Seguier D; Adams ES; Michael Z; Abreu A; Jack Tay K; Ward JF; Shinohara K; Katz AE; Villers A; Chin JL; Stricker PD; Baco E; Macek P; Ahmad AE; Chiu PKF; Crawford ED; Rogers CG; Futterer JJ; Rais-Bahrami S; Robertson CN; Hadaschik B; Marra G; Valerio M; Chong KT; Kasivisvanathan V; Tan WP; Lomas D; Walz J; Guimaraes GC; Mertziotis NI; Becher E; Finelli A; Kasraeian A; Lebastchi AH; Vora A; Rosen MA; Bakir B; Arcot R; Yee S; Netsch C; Meng X; de Reijke TM; Tan YG; Regusci S; Benjamin TGR; Olivares R; Noureldin M; Bianco FJ; Sivaraman A; Kim FJ; Given RW; Dason S; Sheetz TJ; Shoji S; Schulman A; Royce P; Shah TT; Scionti S; Salomon G; Laguna P; Tourinho-Barbosa R; Aminsharifi A; Cathelineau X; Gontero P; Stabile A; Grummet J; Ledbetter L; Graton M; Stephen Jones J; Polascik TJ;
Eur Urol; 2023 Dec; 84(6):547-560. PubMed ID: 37419773
[TBL] [Abstract][Full Text] [Related]
19. Propensity Score-Matched Comparison of Partial to Whole-Gland Cryotherapy for Intermediate-Risk Prostate Cancer: An Analysis of the Cryo On-Line Data Registry Data.
Tay KJ; Polascik TJ; Elshafei A; Tsivian E; Jones JS
J Endourol; 2017 Jun; 31(6):564-571. PubMed ID: 28385075
[TBL] [Abstract][Full Text] [Related]
20. Definition of biochemical success following primary whole gland prostate cryoablation.
Levy DA; Ross AE; ElShafei A; Krishnan N; Hatem A; Jones JS
J Urol; 2014 Nov; 192(5):1380-4. PubMed ID: 24813344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
